Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.54 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28107119 | 1.00 | ALDH1A1 (0.63) | ALDH1A1KDM4ESCN3ASPHK1MAOA | |
| SCHEMBL28952343 | 0.96 | ALDH1A1 (0.69) | ALDH1A1KDM4ESCN3ASPHK1MAOA | |
| SCHEMBL1818801 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EPTGER4TEAD1SMN1; SMN2 | |
| SCHEMBL2032041 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EPTGER4TEAD1SMN1; SMN2 | |
| SCHEMBL21618307 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EPTGER4TEAD1SMN1; SMN2 | |
| SCHEMBL7314623 | 0.85 | ALDH1A1 (0.66) | ALDH1A1KDM4ESCN3ASPHK1MAOA | |
| SCHEMBL28107109 | 0.85 | ALDH1A1 (0.66) | ALDH1A1KDM4ESCN3ASPHK1MAOA | |
| SCHEMBL9151576 | 0.85 | MAOB (0.64) | ALDH1A1KDM4ESCN3ASPHK1MAOA | |
| SCHEMBL9147565 | 0.85 | MAOB (0.64) | ALDH1A1KDM4ESCN3ASPHK1MAOA | |
| SCHEMBL4844700 | 0.83 | SPHK1 (0.59) | SCN3ASPHK1MAOAMAOBGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | ALDH1A1 4627/4885KDM4E 1820/4885SCN3A 403/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885KDM4E 898/4885SCN3A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.